BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35535426)

  • 1. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.
    Korsic S; Levasic N; Dezman R; Zupan LAL; Trotovsek B; Jansa R; Smid A; Popovic P
    Radiol Oncol; 2022 Aug; 56(3):311-318. PubMed ID: 35535426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
    Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
    AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
    [No Abstract]   [Full Text] [Related]  

  • 3. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
    Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
    Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
    Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.
    Malagari Κ; Kiakidis T; Moschouris H; Deutsch M; Tanteles S; Pantou E; Panagiotou I; Koskinas J; Glantzounis GK; Alexopoulou A; Filippiadis D; Brountzos E; Kelekis N
    Cardiovasc Intervent Radiol; 2023 Mar; 46(3):337-349. PubMed ID: 36653660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.
    Urbano J; Echevarria-Uraga JJ; Ciampi-Dopazo JJ; Sánchez-Corral JA; Cobos Alonso J; Anton-Ladislao A; Peña-Baranda B; Nacarino-Mejias V; González-Costero R; Muñoz Ruiz-Canela JJ; Pérez-Cuesta J; Lanciego C; de Gregorio MA
    Eur J Radiol; 2020 May; 126():108966. PubMed ID: 32278280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone.
    Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Artzner C; Bitzer M; Horger M; Grözinger G
    Eur J Radiol; 2021 Jul; 140():109768. PubMed ID: 33991970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.
    Albrecht KC; Aschenbach R; Diamantis I; Eckardt N; Teichgräber U
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):23-32. PubMed ID: 32880029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
    Huo YR; Xiang H; Chan MV; Chan C
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma.
    Chang KH; Hwang ZA; Chang PY; Lin HH; Shih YL; Chang WC; Huang GS; Hsu HH
    Sci Rep; 2019 Dec; 9(1):20032. PubMed ID: 31882969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control.
    Popovic P; Stabuc B; Jansa R; Garbajs M
    Radiol Oncol; 2016 Dec; 50(4):418-426. PubMed ID: 27904450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarubicin
    Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T
    World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 18. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
    Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.